Wednesday - May 14, 2025
Boston, April 25, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in hybrid care enablement, announced that the company will participate in the Needham Technology, Media and Consumer Conference.
Robert Shepardson, Amwell chief financial officer, will participate in a fireside chat on Tuesday, May 14, at a time to be determined, along with one-on-one investor meetings throughout the day.
An audio webcast of the fireside chat will be available at investors.amwell.com.
About Amwell
Amwell is a leading hybrid care delivery enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. We offer a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With nearly two decades of experience, Amwell powers the digital care of more than 50 health plans, which collectively represent more than 100 million covered lives, and many of the nation’s largest health systems. For more information, please visit https://business.amwell.com/.
©2024 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, ConvergeTM, CarepointTM and the Amwell Logo are registered trademarks or trademarks of American Well Corporation.
Last Trade: | US$7.45 |
Daily Change: | -0.15 -1.97 |
Daily Volume: | 7,204 |
Market Cap: | US$101.840M |
May 01, 2025 February 12, 2025 January 15, 2025 December 18, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load